Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HIPEC and Chemoradiation for Gastric Cancer
NCT04308837Phase 2Unknown
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Dec 2018
- Primary completion
- Aug 2025
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection and carboplatin in gastric cancer (GC), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Pathological Response. Status: unknown.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04308837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308837.